Unknown

Dataset Information

0

Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.


ABSTRACT: Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo. Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH. For compounds containing naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing. Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metabolism in human liver microsomes and which showed prolonged exposure in mice. Compound 21 (DSM74), containing p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration. This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy.

SUBMITTER: Gujjar R 

PROVIDER: S-EPMC2746568 | biostudies-literature | 2009 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.

Gujjar Ramesh R   Marwaha Alka A   El Mazouni Farah F   White John J   White Karen L KL   Creason Sharon S   Shackleford David M DM   Baldwin Jeffrey J   Charman William N WN   Buckner Frederick S FS   Charman Susan S   Rathod Pradipsinh K PK   Phillips Margaret A MA  

Journal of medicinal chemistry 20090401 7


Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo. Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH. For  ...[more]

Similar Datasets

| S-EPMC3124361 | biostudies-literature
| S-EPMC5148661 | biostudies-literature
| S-EPMC2624570 | biostudies-literature
| S-EPMC6120730 | biostudies-literature
| S-EPMC4079327 | biostudies-literature
| S-EPMC3446820 | biostudies-literature
| S-EPMC9228440 | biostudies-literature
| S-EPMC4904246 | biostudies-literature
| S-EPMC10513951 | biostudies-literature
| S-EPMC3156099 | biostudies-literature